SAMIL PHARMACEUTICAL CO.,LTD CEO group extends share-backed loan, pledged shares at 3.16%
AI summary · Not investment advice
The stake of the CEO and 13 related parties in SAMIL PHARMACEUTICAL CO.,LTD was unchanged at 25.96%, while pledged shares fell from 797,392 to 686,203.
Total under contracts
686,203 shares
Previous 3.68% → now 3.16%
Key facts
- Stake
- 25.96%Same as previous
- Reporting holder
- The CEO and 13 related parties
- Purpose of holding
- To influence management
- Relationship with issuer
- Registered executive
- Report type
- Amendment
- Reason for report
- Extension of a share-backed loan by a related party
- Shares held
- 5,630,509 sharesSame as previous
- Reason for amendment
- Extension of a share-backed loan by a related party
- Previous shares under major contracts
- 797,392 shares
- Shares under major contracts
- 686,203 shares
- Reporting obligation date
- Oct 6, 2026
Commentary
AI commentary · Not investment advice
What happened
The CEO of SAMIL PHARMACEUTICAL and 13 related parties filed an amended report because the terms of their share-backed loans changed. A related party's loan from a securities firm was extended. The group's 5,630,509 shares and 25.96% stake did not change. Pledged shares fell from 797,392 to 686,203.
In the company's terms
SAMIL PHARMACEUTICAL has 21,691,811 voting shares in issue. Pledged shares fell from 3.68% to 3.16% of the total. The remaining lenders are two securities firms and a bank. Interest rates range from 5.4% to 6.9%, with a collateral maintenance ratio of 150%.
What changes for shareholders
The earliest loan matures on October 26, 2026. The others end between January 4 and 11, 2027. The stated purpose is to influence management.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
S